Serum Ischemia-Modified Albumin Levels, Myeloperoxidase Activity and Peripheral Blood Mononuclear cells in Autism Spectrum Disorder (ASD)
Journal of Autism and Developmental Disorders, cilt.51, sa.7, ss.2511-2517, 2021 (SSCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 51 Sayı: 7
- Basım Tarihi: 2021
- Doi Numarası: 10.1007/s10803-020-04740-9
- Dergi Adı: Journal of Autism and Developmental Disorders
- Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, Academic Search Premier, ASSIA, PASCAL, BIOSIS, Child Development & Adolescent Studies, CINAHL, EBSCO Education Source, Education Abstracts, Educational research abstracts (ERA), EMBASE, ERIC (Education Resources Information Center), Linguistics & Language Behavior Abstracts, MEDLINE, Psycinfo, Public Affairs Index
- Sayfa Sayıları: ss.2511-2517
- Anahtar Kelimeler: ASD, Autism spectrum disorder, Myeloperoxidase, Ischemia-modified albumin, IMA, Neutrophils, Lymphocytes, Monocytes
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.Genetic, neurobiological, neurochemical, environmental factors and their interactions contribute to autism phenotypes. Blood from 48 (age range: 4–17) autism spectrum disorder diagnosed patients (ASD) and 38 age- and gender-matched healthy control subjects was analyzed for numbers of neutrophils, lymphocytes, monocytes, albumin, serum Ischemia-Modified Albumin (IMA) levels and myeloperoxidase activity. The serum IMA levels, myeloperoxidase activity and peripheral blood mononuclear cells count were significantly higher in ASD cases than in the control subjects. There were no significant differences in albumin levels between the patient and control groups. These results suggest that the immune system, oxidative stress and myeloperoxidase activity may be activated in ASD. There is a clinical benefit from the early detection of ASD using myeloperoxidase activity, IMA levels and monocyte counts.